Clinical Trial Update: MB-CART19.1 in Refractory SLE [Phase 1, Phase 2]

View source ↗

Summary

Miltenyi Biomedicine's MB-CART19.1 is being studied in Phase 1/2 trials for refractory systemic lupus erythematosus, with recruitment ongoing. The study investi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• MB-CART19.1

Snippet

Sponsor: Miltenyi Biomedicine GmbH | Conditions: SLE - Systemic Lupus Erythematosus | Phase 1, Phase 2 | Status: RECRUITING